- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02612545
Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia
A Multi-Site, Open-Label, Randomized Trial to Assess the Efficacy, Safety, and Tolerability of Dihydroartemisinin-Piperaquine Plus Mefloquine Compared to Dihydroartemisinin-Piperaquine or Artesunate-Mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia
Background:
Malaria is an illness caused by a parasite that enters people s bodies when a mosquito bites them. It can cause fevers, headaches, body aches, and weakness. If not treated, it can make some people very ill. Malaria can be cured. A mix of 2 drugs that has worked well in the past is not working as well in some parts of Cambodia. Researchers want to see if a mix of 3 drugs works better and is safe.
Objectives:
To see if a 3-drug mix can be used to treat malaria in areas where a 2-drug mix is less effective.
Eligibility:
People aged 2 65 years with mild malaria in Pursat, Preah Vihear, and Ratanakiri Provinces in Cambodia.
Design:
Participants will be screened with medical history, physical exam, urine and blood tests, and an electrocardiogram (ECG). For this, electrodes will be placed on their skin to check their heartbeat.
Participants will spend about 5 nights in the hospital. They will have physical exams and will complete symptom questionnaires daily. They will give blood periodically throughout their stay. For this, a thin plastic tube is placed in an arm vein for the first day, and blood draws using a needle are done after that.
Participants will get either a 2-drug mix or a 3-drug mix for 3 days. They will have 2 ECGs each day of receiving the drugs.
Participants will have follow-up visits once a week over 5 weeks. At these visits, they will have a physical exam and have blood taken. If they have any signs of malaria, they will be re-treated.
The study will last up to 42 days.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Phnom Penh, Cambodia
- National Center for Parasitology, Entomology, and Malaria Controk, Ministry of H
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION:
- Age 2 to 65 years
- Uncomplicated falciparum malaria, confirmed by the presence of asexual P.falciparum parasites (alone or mixed with other Plasmodium species) on blood film
- Asexual P. falciparum count <200,000/ L at screening
- Tympanic temperature greater than or equal to 37.5 (Infinite)C or history of fever in the previous 24 hours
- Written informed consent from adults or the parents/guardians of children
EXCLUSION:
- Signs of severe malaria, defined as one or more of the following:
Glasgow Coma Scale less than or equal to 10/15 in adults; Blantyre Coma Scale less than or equal to 3/5 in children
- Witnessed convulsions
- Severe prostration
- Shock (poor perfusion, cool peripheries as deemed by the study physician)
- Hematocrit <20%
- Jaundice
- Respiratory distress (labored breathing, nasal flaring, intercostal retraction)
- Anuria for 24 hours or more
- Repetitive vomiting
- Hematocrit <25%
- Acute illness other than uncomplicated falciparum malaria requiring treatment
- Pregnancy or breastfeeding
- Patients who have received an ART derivative or ACT in the previous 7 days
- Treatment with MQ in the previous 60 days
- History of allergy or known contraindication to ART, PPQ, MQ, or PMQ
- Splenectomy
- Documented or claimed history of cardiac arrythmias, neuropsychiatric disease
- Earlier participation in this trial
- Any condition that in the opinion of the investigator would render the patient unable to comply with the protocol (e.g., psychiatric disease)
- Any health condition that in the opinion of the investigator would confound data analysis (e.g., patients known to be HIV-infected or to have AIDS) or pose unnecessary exposure risks to the patient (e.g., severe malnutrition)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: ACT
Patients randomized to ACT will receive DHA-PPQ only
|
Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia
|
EXPERIMENTAL: TACT
Patients randomized to TACT will receive DHA-PPQ plus MQ
|
Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia
ACT partner drug
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Compare the efficacy of TACT versus ACT, as defined by an adequate clinical and parasitological response (ACPR), defined as: absence of parasitemia on Day 42 (detected by blood smear, not PCR), irrespective of tympanic temperature, in subjects w...
Time Frame: Day 42 post enrollment
|
Day 42 post enrollment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Compare parasite and fever clearance rates/times following TACT versus ACT
Time Frame: Days 0-6 post enrollment
|
Days 0-6 post enrollment
|
Compare the safety and tolerability of TACT versus ACT
Time Frame: Day 0-6 post enrollment
|
Day 0-6 post enrollment
|
Compare ECG QTc prolongation following TACT versus ACT
Time Frame: Days 0-2 post enrollment
|
Days 0-2 post enrollment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Thomas E Wellems, M.D., National Institute of Allergy and Infectious Diseases (NIAID)
Publications and helpful links
General Publications
- Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, Rahman MR, Hasan MM, Islam A, Miotto O, Amato R, MacInnis B, Stalker J, Kwiatkowski DP, Bozdech Z, Jeeyapant A, Cheah PY, Sakulthaew T, Chalk J, Intharabut B, Silamut K, Lee SJ, Vihokhern B, Kunasol C, Imwong M, Tarning J, Taylor WJ, Yeung S, Woodrow CJ, Flegg JA, Das D, Smith J, Venkatesan M, Plowe CV, Stepniewska K, Guerin PJ, Dondorp AM, Day NP, White NJ; Tracking Resistance to Artemisinin Collaboration (TRAC). Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014 Jul 31;371(5):411-23. doi: 10.1056/NEJMoa1314981. Erratum In: N Engl J Med. 2014 Aug 21;371(8):786.
- Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, Kim S, Witkowski B, Duru V, Domergue A, Khim N, Ringwald P, Menard D. Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment. Antimicrob Agents Chemother. 2015 Aug;59(8):4719-26. doi: 10.1128/AAC.00835-15. Epub 2015 May 26.
- Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, Se Y, Chann S, Ittiverakul M, Sia-ngam P, Kuntawunginn W, Arsanok M, Buathong N, Chaorattanakawee S, Gosi P, Ta-aksorn W, Chanarat N, Sundrakes S, Kong N, Heng TK, Nou S, Teja-isavadharm P, Pichyangkul S, Phann ST, Balasubramanian S, Juliano JJ, Meshnick SR, Chour CM, Prom S, Lanteri CA, Lon C, Saunders DL. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015 Jun;15(6):683-91. doi: 10.1016/S1473-3099(15)70049-6. Epub 2015 Apr 12.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 999916023
- 16-I-N023
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Falciparum Malaria
-
Novartis PharmaceuticalsCompletedAcute Uncomplicated P. Falciparum Malaria
-
Novartis PharmaceuticalsMedicines for Malaria VentureCompletedAcute Uncomplicated Falciparum MalariaBurkina Faso, Benin, Congo, Nigeria, Togo
-
Novartis PharmaceuticalsMedicines for Malaria VentureCompletedAcute Uncomplicated Plasmodium Falciparum MalariaThailand, Gabon, Mali, Uganda, Burkina Faso, India, Kenya, Mozambique, Vietnam
-
Jomaa Pharma GmbHCentre de Recherche Médicale de LambarénéUnknownOral Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria
-
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...RecruitingAcute MalariaBurkina Faso, Gabon, Mozambique, Uganda
-
University of OxfordTerminatedP. Falciparum MalariaThailand
-
National Institute of Allergy and Infectious Diseases...CompletedAccute Falciparum MalariaMali
-
Medical University of ViennaInternational Centre for Diarrhoeal Disease Research, Bangladesh; Armed Forces...CompletedAzithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in BangladeshUncomplicated Falciparum MalariaBangladesh
-
Medecins Sans Frontieres, NetherlandsUniversity of Oxford; Mahidol University; Disease Control, Department of Health...UnknownUncomplicated Falciparum MalariaMyanmar
-
University of OxfordNanyang Technological University; Texas Biomedical Research InstituteCompletedP. Falciparum Malaria | P. Falciparum Malaria Mixed InfectionThailand
Clinical Trials on Dihydroartemisinin-piperaquine (DHA-PPQ)
-
Barcelona Institute for Global HealthMedical University of Vienna; Centro de Investigação em Saúde de Manhiça; Centre... and other collaboratorsCompletedHIV/AIDS | Pregnancy Related | MalariaGabon, Mozambique
-
JhpiegoUnited States Agency for International Development (USAID); Centers for Disease... and other collaboratorsCompleted
-
University of California, San FranciscoEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHIV Infection | Drug-Drug InteractionUganda
-
Malaria ConsortiumCenters for Disease Control and Prevention; World Health Organization; National... and other collaboratorsCompleted
-
National Institute of Malariology, Parasitology...Institute of Tropical Medicine, BelgiumCompleted
-
London School of Hygiene and Tropical MedicineMedical Research Council Unit, The GambiaTerminated
-
University of OxfordMahidol Oxford Tropical Medicine Research UnitCompleted
-
Armed Forces Research Institute of Medical Sciences...National Center for Parasitology, Entomology, and Malaria Control (CNM); Ministry...Active, not recruitingParasitic Diseases | MalariaCambodia
-
Indonesia UniversityCompleted
-
Liverpool School of Tropical MedicineThe Research Council of Norway; Makerere University; Kenya Medical Research InstituteCompleted